Fast-Track Status: AMG 531 for ITP, AMG 706 for Stromal Tumors

Stromal Tumors

Amgen, Inc., has announced a “fast-track” designation for two experimental therapies, AMG 531 and AMG 706. canadian antibiotics

AMG 531, which received orphan drug designation in 2003, represents a new approach to treating immune thrombo-cytopenic purpura (ITP), an autoimmune bleeding disorder. AMG 706 is in phase 2 trials for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs), which are fatal.